MIRA INFORM REPORT
|
Report Date : |
17.11.2008 |
IDENTIFICATION
DETAILS
|
Name : |
DAEWOONG PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
223-23, Sangdaewon 1-dong, Jungwon-gu,
Seongnam-si, Gyeonggi-do |
|
|
|
|
Country : |
Korea |
|
|
|
|
Financials (as on) : |
30.09.2008 |
|
|
|
|
Date of Incorporation : |
01.10.2002 |
|
|
|
|
Com. Reg. No.: |
124-86-01143 |
|
|
|
|
Legal Form : |
Listed Company |
|
|
|
|
Line of Business : |
Manufacture of Medicinal Chemicals and Antibiotics |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually Correct |
|
|
|
|
Litigation : |
Clear |
Basic
|
Company
Name |
DAEWOONG
PHARMACEUTICAL CO., LTD. |
|
Registered Address |
223-23, Sangdaewon 1-dong, Jungwon-gu,
Seongnam-si, Gyeonggi-do, Korea |
|
Zip Code |
462-807 |
|
Tel |
+82-31-741-7700~4 |
|
Fax |
+82-31-749-5535 |
|
E-mail |
global@daewoong.co.kr david_kim@daewoong.co.kr;stomeve@daewoong.co.kr |
|
Website |
www.daewoong.com |
|
Trading Address |
163-3, Samsung-dong, Gangnam-gu, .Seoul,
Korea |
|
Tel |
+82-2-550-8800 |
|
Fax |
+82-2-550-8400 |
|
Other Address-R&D Center |
501-2, Samgye-ri, Pogok-myon, Yongin,
Gyunggi-do, Korea |
|
Tel |
+82-31-334-3200 |
|
Fax |
+82-31-332-7152 |
|
Other Address- Hyangnam Factory |
906-10, Sangshin-ri, Hyangnam-myon , Hwasung gun, Gyunggi-do, Korea |
|
Tel |
+82-31-353-5911 |
|
Fax |
+82-31-353-5916 |
|
Other Address- Anseong Factory |
547-4 Singeonji-dong
,Anseong-si,.Gyeonggi-do, Korea |
|
Tel |
+82-31-678-1800 |
|
Fax |
+82-31-678-1866 |
|
Other Address-Seoul Seobu Branch |
449-5, Seogyo-dong,
Mapo-gu, Seoul, Korea |
|
Tel |
+82-2-3141-2145 |
|
Fax |
+82-2-3141-2153 |
|
Other Address- Seoul Bukbu Branch |
2, Muk-dong, Jungnang-gu,
Seoul, Korea |
|
Tel |
+82-2-3296-0595 |
|
Fax |
+82-2-3296-0599 |
|
Other Address-Gyeongin Branch |
366-5, Songnae-dong,
Sosa-gu, Bucheon-si, Gyeonggi-do, Korea |
|
Tel |
+82-32-611-8039 |
|
Fax |
+82-32-654-3994 |
|
Other Address- Gyeonggi Branch |
Rm.403, Chungmyung Pountel,
Yeongtong-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do, Korea |
|
Tel |
+82-31-204-1096 |
|
Fax |
+82-31-204-1094 |
|
Other Address- Gangwon Branch |
1689-1, Gwanseol-dong,
Wonju-si, Gangwon-do, Korea |
|
Tel |
+82-33-766-0195 |
|
Fax |
+82-33-766-0196 |
|
Other Address-Cheongju Branch |
1695, Yongam-dong,
Sangdang-gu, Cheongju-si, Chungbuk, Korea |
|
Tel |
+82-43-287-3354 |
|
Fax |
+82-43-284-4019 |
|
Other Address- Gwangju Branch |
851-10, Duam-dong,
Buk-gu, Gwangju, Korea |
|
Tel |
+82-62-263-7511~3 |
|
Fax |
+82-62-263-7514 |
|
Other Address- Jeonju Branch |
766, Seosin-dong,
Wansan-gu, Jeonju-si, Jeonbuk, Korea |
|
Tel |
+82-63-276-1386 |
|
Fax |
+82-63-276-1389 |
|
Other Address- Jeju Branch |
906-5, Nohyeong-dong,
Jeju-si, Jeju-do, Korea |
|
Tel |
+82-64-747-1979 |
|
Fax |
+82-64-748-1978 |
|
Other Address- Daegu Branch |
10-7, Sinmae-dong,
Suseong-gu, Daegu, Korea |
|
Tel |
+82-53-767-5581 |
|
Fax |
+82-53-768-0881 |
|
Other Address- Busan Branch |
1160-1, Choryang 3-dong,
Dong-gu, Busan, Korea |
|
Tel |
+82-51-466-6725 |
|
Fax |
+82-51-466-6729 |
|
Other Address- Ulsan Branch |
848-2, Mugeo-dong,
Nam-gu, Ulsan, Korea |
|
Tel |
+82-52-249-6725 |
|
Fax |
+82-52-249-6726 |
|
Other Address- Gyeongsangnam Branch |
303-3, Dogye-dong, Changwon-si,
Gyeongsangnam-do, Korea |
|
Tel |
+82-55-277-9545 |
|
Fax |
+82-55-277-9548 |
|
Type |
Export/Import |
|
Industry |
Manufacture of Medicinal Chemicals and Antibiotics |
|
Main Business |
Medicine |
|
Established (mm/dd/yyyy) |
10/01/2002 |
The Subject owns
the premises of Hyangnam Factory, Trading Address and R&D Center.
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Antiulcer and related gastrointestinal GI drugs(51171900) |
|
Sell |
Antianemic drugs(51131500) |
|
Sell |
Antibiotics(51101500) |
|
Sell |
Drugs used for respiratory tract
disorders(51161700) |
|
Sell |
Mouth fresheners(53131509) |
|
Sell |
Cough and cold and antiallergy
products(51161800) |
|
Sell |
Hormones and antihormones(51111800) |
|
Buy |
Nonsteroidal anti inflammatory drugs
NSAIDs(51142100) |
|
Buy |
Dexchlorpheniramine maleate(51161603) |
|
Buy |
Acetaminophen(51142001) |
|
Buy |
Antifungal drugs(51101800) |
|
Buy |
Antibiotics(51101500) |
|
Buy |
Non narcotic analgesics and
antipyretics(51142000) |
|
Buy |
Ipratropium bromide(51161705) |
|
Buy |
Preservatives(12164501) |
|
Buy |
Ephedrine(51151741) |
|
Buy |
Cetirizine(51161615) |
|
Buy |
Mefenamic acid(51142012) |
|
Buy |
Ibuprofen(51142106) |
CEO’s
|
Name |
Yun Jae-Seung |
|
Date of Birth |
11/09/1962 |
|
Title |
Vice Chairman |
|
Sex |
Male |
|
Nationality |
Korean |
Profiles
|
Capital |
25,380,547,500 KRW |
||||||||||||||||||
|
Employees |
1,254 |
||||||||||||||||||
|
Formation |
Listed Company (Korea Stock Exchange :
069620) as of 11/02/2002 A Company of DAEWOONG GROUP |
||||||||||||||||||
|
Bank Details |
Citi Bank, Korea Korea Exchange Bank Shinhan bank |
||||||||||||||||||
|
Corporate Registered No. |
134811-0075342 |
||||||||||||||||||
|
Business Registered No. |
124-86-01143 |
||||||||||||||||||
|
Permit & Licenses |
2003 ISO 14001 Int’l Trade No.: 45101917 |
||||||||||||||||||
|
Shareholder Position |
|
||||||||||||||||||
|
Company History |
2007
Family-friendly company, announced by the Cheongwadae 2007 Being
selected as the best practice company in labor-management relations 2007 Being selected
as the excellent productivity increase company in the National Productivity
Innovation Competition 2007 Introducing
the four-day workweek talented employee upbringing program to Hyangnam plant 2007 Sales of the
100mg high content CoQ10 for the first time in Korea 2007 Ursa’s
launching in Vietnam 2007 Sales of
NVU, a treatment for obesity 2006 Obtained
Technology Patent on Moxicle 2006 Obtained
Patent(Manufacture and Substance) on Coenzyme Q10 2006 Obtained
Composition Patent on EGF in Japan 2005 CoenzymeQ10
Selected as a World-Class Product by the Korean Ministry of Commerce,
Industry, and Energy 2005 Conducted
Joint Research with Haptogen in Scotland on Alternative to Antibiotic
Treatment 2005 Conducted
Joint Research with Peptron on Treatment for Acromegaly 2005 Launched
Olmetec (Sankyo) , Angiotensin II Receptor Antagonist 2004 Acquired
Approval to Sell Easyef, Diabetic Foot Ulcerant by Jordian FDA 2004 Launched
Asacol (Tillotts) for IBD Treatment 2004 Acquired Approval
to Sell Easyef for Functional Cosmeceuticals 2003 Started
Co-Promotion of Cialis with Eli Lilly 2003 Started
Co-Marketing of Diabex/Gluriad with Merck Sante. 2003 Second
Company in the World to Develop CoenzymeQ10 (Acquired ISO14001) 2003 Acquired
Occupational Safety and Health Management System (OS-HMS) Certificate 05/30/2003 Moved
to the present HQ address from 906-10, Sangsin-ri, Hyangnam-eup, Hwaseong-si,
Gyeonggi-do, Korea 2003 Completed
Construction of Advanced Automated Material Handling Center 2002 Daewoong
Pharmaceutical Co. Ltd. Split into DAEWOONG CO. LTD. and DAEWOONG
PHARMACEUTICAL CO. LTD. 2002 Launched
Gasmotin (Dainippon) for Functional Dyspepsia 2002 Received
Economic Justice Business Award from the Korean Fair Trade Commission 2001 Launched
Easyef, the First New Bio-pharmaceutical in Korea |
||||||||||||||||||
|
1999 Obtained
BGMP Approval in Korea. 1998 Introduced
ERP System to Daewoong. 1997 Received
Chungmugong Award for Easyef by the Korean Intellectual Property Office. 1995 Launched Airtal
(Almirall), NSAID. 1994 Raw Material
of Gomcillin Acquires FDA Approval for the First Time in Korea. 1992 Established
New Ultra-modern Pharmaceutical Plant at Hyangnam with a Space Area of 21,046
Square Meters. 1990 Established
Daewoong International Corporation. 1989 Established
Technical Cooperation with Tongrentang in China. 1988 Relocated
Headquarters to Samsung-Dong, Seoul. 1987 Obtained
First Genetic Engineering Patent in Korea.
1986 Obtained
Korean GMP Approval for Daewoong Plants.
1985 Contracted
with DuPont USA for Medical Devices. 1984 Established
'Daewoong Endowment Foundation' for Education and Social Welfare. 1983 Established
Daewoong Chemical Co,.Ltd for Bulk Pharmaceutical Products. 1983 Established
Daewoong Central R&D Institute. 1982 Established
R.P. Scherer Korea Co.Ltd. Co, a Joint Venture with R.P. Scherer Corporation
(US). 1982 Received
'The Gold Tower Order of Industrial Merit' by the Korean. 1981 Established
Daewoong Lilly Pharmaceutical Co., Ltd., a Joint Venture with Eli Lilly & Co. (US). 1978 Obtained
First Genetic Engineering Patent in Korea.
1974 Established
Annex Pharmaceutical Research Center .
1973 Offered
Company Shares to the Public. 1972 Transferred
Headquarters to Seou. 1972 Transferred
a Plant from Pusan to Sungnam, Kyoung-ki Do.
1966 Chairman
Y.H. Yoon Acquires Daewoong Pharmaceutical Co., Ltd. 1961 Established
Daehan Vitamin Chemical Industry Co., Ltd.
1945 Established
Chosun Liver-oil Pharmaceutical Industry Co., Ltd. |
The Subject Company
is a Korea-based manufacturer engaged in the provision of pharmaceutical
products. The Company mainly provides prescription and over-the-counter drugs,
including hypertension remedies, antidote for liver toxicity, digestion remedies,
remedies for cerebrovascular disease, nervous and skeletal system remedies,
antibiotics, antifungal agents, remedies for gastrointestinal systems, remedies
for osteoporosis, respiratory disease remedies, diabetes remedies, nutrition,
eye drops and others. It also provides healthcare products such as
lactobacilli, cold remedies with vitamin C and remedies for obesity, as well as
toothpaste, moisture creams and other miscellaneous products.
Management
|
Job Description |
Title |
Name |
Nationality |
Date of Birth |
Education |
|
Vice Chairman & CEO |
Mr. |
Yun Jae-Seung |
Korean |
1962.11.09 |
Seoul National University |
|
President & CEO |
Mr. |
Lee Jong-Wook |
Korean |
1949.03.10 |
Seoul National University |
|
Chairman |
Mr. |
Yun Young-Hwan |
Korean |
1934.03.30 |
Sungkyunkwan University |
|
Executive Director |
Mr. |
Lee Jin-Ho |
Korean |
1952.08.28 |
Sungkyunkwan University |
|
Executive Director |
Mr. |
Park Jae-Hong |
Korean |
1962.07.27 |
Seoul National University |
|
Outside Director |
Mr. |
Chang Choon |
Korean |
1940.06.10 |
Sungkyunkwan University |
|
Outside Director |
Mr. |
Phong Jun-Pyo |
Korean |
1967.12.18 |
Yonsei University |
|
Outside Director |
Mr. |
Lee Chung-Ho |
Korean |
1955.07.01 |
Seoul National University |
|
Auditor |
Mr. |
Lee Seung-Han |
Korean |
1969.06.20 |
Seoul National University |
Financials
|
|
|
|
Unit: KRW |
|
Year |
Sales |
Assets |
Net income |
|
484,242,259,221 |
386,873,244,791 |
58,983,018,162 |
|
|
03/2007 |
400,443,392,715 |
321,845,504,956 |
48,523,053,767 |
|
032006 |
338,165,956,277 |
270,645,344,606 |
35,236,107,861 |
|
032005 |
280,396,027,247 |
238,763,381,959 |
25,878,188,318 |
|
032004 |
248,416,150,017 |
233,056,569,717 |
14,828,678,255 |
Financial Description
|
|
Unit: KRW |
|
Authorized
Capital |
80,000,000,000 |
|
Paid-Up
Capital |
25,380,547,500 |
|
Total Issues Shares |
10,152,219 |
Balance
Sheet
|
Unit : Korean Won |
04/01/2008~09/30/2008 |
As of 03/31/2008 |
As of 03/31/2007 |
|
Total Assets |
462,146,004,722 |
386,873,244,791 |
321,845,504,956 |
|
Current Assets |
269,680,425,645 |
228,477,053,070 |
201,278,527,567 |
|
-Quick Assets |
195,805,953,660 |
155,880,068,326 |
156,297,286,813 |
|
-Inventories |
73,874,471,985 |
72,596,984,744 |
44,981,240,754 |
|
Fixed Assets |
192,465,579,077 |
158,396,191,721 |
120,566,977,389 |
|
-Investment |
24,867,462,367 |
27,350,485,040 |
23,030,051,091 |
|
-Tangibles |
131,152,718,982 |
112,520,965,849 |
86,051,114,862 |
|
-Intangibles |
4,367,695,717 |
3,745,417,079 |
4,903,791,669 |
|
-Others |
32,077,702,011 |
14,779,323,753 |
6,582,019,767 |
|
Total Liabilities |
190,848,426,422 |
123,152,002,329 |
109,352,563,553 |
|
Current Liabilities |
118,844,828,157 |
85,463,638,235 |
101,272,069,351 |
|
Fixed Liabilities |
72,003,598,265 |
37,688,364,094 |
8,080,494,202 |
|
Capital Stock |
25,380,547,500 |
24,696,345,000 |
24,696,345,000 |
|
Capital Surplus |
104,006,383,057 |
104,690,585,557 |
104,639,503,177 |
|
Profit Surplus |
170,322,873,498 |
154,083,097,282 |
102,398,258,320 |
|
Capital Adjustment |
(-)28,412,225,755 |
(-)19,748,785,377 |
(-)19,241,165,094 |
|
Total Equity |
271,297,578,300 |
263,721,242,462 |
212,492,941,403 |
|
Liab. & Shareholder’s Equity |
462,146,004,722 |
386,873,244,791 |
321,845,504,956 |
|
Current
Liabilities |
118,844,828,157 |
85,463,638,235 |
101,272,069,351 |
|
Trade Payables |
46,681,228,138 |
39,272,101,827 |
32,732,853,693 |
|
Account Payables |
9,815,185,908 |
13,928,617,337 |
13,703,125,511 |
|
Accrued Expenses |
477,804,022 |
141,805,946 |
5,820,652 |
|
Withholdings |
1,545,679,642 |
1,574,058,951 |
1,911,517,947 |
|
VAT Withhold |
4,270,179,335 |
5,195,589,161 |
5,360,827,045 |
|
Leasehold Deposit Received |
9,383,291,258 |
8,211,563,229 |
9,010,169,648 |
|
Provision for Refund |
3,245,294,438 |
4,093,175,927 |
4,257,609,183 |
|
Accrued Income Tax |
8,426,165,432 |
12,852,030,969 |
14,317,137,590 |
|
Short-Term Borrowings |
34,999,999,984 |
- |
- |
|
Current Portion of Debentures |
- |
- |
20,000,000,000 |
|
Current Portion of Derivatives |
- |
194,694,888 |
- |
|
Fixed
Liabilities |
72,003,598,265 |
37,688,364,094 |
8,080,494,202 |
|
Debentures |
59,385,000,000 |
29,751,000,000 |
- |
|
Long-Term Withholdings |
187,000,000 |
187,000,000 |
484,170,383 |
|
Provision for Severance &
Retirement |
22,696,844,128 |
21,481,694,880 |
18,269,285,365 |
|
Non-Current Portion of
Deferred Income Tax Credit |
4,256,890,780 |
2,053,158,168 |
1,983,095,107 |
Income
Statement
|
Unit : Korean Won |
04/01/2008~09/30/2008 |
As of 03/31/2008 |
As of 03/31/2007 |
|
Sales |
269,931,693,742 |
484,242,259,221 |
400,443,392,715 |
|
Cost of Sold Goods |
137,503,802,237 |
223,960,069,047 |
179,564,233,134 |
|
Gross Profit |
132,427,891,505 |
260,282,190,174 |
220,879,159,581 |
|
Selling & Admin. Expenses |
101,267,324,510 |
186,036,330,527 |
153,833,530,032 |
|
Operating Income |
31,160,566,995 |
74,245,859,647 |
67,045,629,549 |
|
Non-Operating Income |
19,886,500,924 |
15,287,687,908 |
8,478,039,369 |
|
Non-Operating expenses |
19,829,725,054 |
9,801,235,649 |
7,812,447,375 |
|
Ordinary Income |
31,217,342,865 |
79,732,311,906 |
67,711,221,543 |
|
Special Income |
|
|
|
|
Income Before Taxes |
31,217,342,865 |
79,732,311,906 |
67,711,221,543 |
|
Income Taxes Expenses |
7,679,387,449 |
20,749,293,744 |
19,188,167,776 |
|
Net Income |
23,537,955,416 |
58,983,018,162 |
48,523,053,767 |
Cash
Flows
|
Unit : Korean Won |
04/01/2008~09/30/2008 |
As of 03/31/2008 |
As of 03/31/2007 |
|
Cash Flows from Operating |
11,543,800,331 |
26,406,952,474 |
48,962,960,157 |
|
-Net Income |
23,537,955,416 |
58,983,018,162 |
48,523,053,767 |
|
-Exp. without Cash Outflow |
25,405,304,317 |
26,555,784,203 |
20,104,080,642 |
|
-Sales without Cash Inflows |
(-)13,781,586,356 |
(-)8,322,598,548 |
(-)1,754,292,019 |
|
-Changes in Asset/ & Liability |
(-)23,617,873,046 |
(-)50,809,251,343 |
(-)17,909,882,233 |
|
Cash Flows from Investing |
(-)30,084,822,149 |
(-)38,603,711,921 |
(-)26,765,281,546 |
|
-Cash Inflow from Investing |
5,755,254,838 |
24,446,259,698 |
15,477,142,802 |
|
-Cash Outflows for Investing |
(-)35,840,076,987 |
(-)63,049,971,619 |
(-)42,242,424,348 |
|
Cash Flows from Financing |
37,654,639,059 |
863,971,720 |
(-)12,007,399,580 |
|
-Cash Inflows from Financing |
53,063,449,941 |
28,162,150,920 |
- |
|
-Cash Outflows from Financing |
(-)15,408,810,882 |
(-)27,298,179,200 |
(-)12,007,399,580 |
|
Increase/Decrease in Cash |
19,113,617,241 |
(-)11,332,787,727 |
10,190,279,031 |
|
Cash at the Beginning of Year |
28,272,418,532 |
39,605,206,259 |
29,414,927,228 |
|
Cash at the End of Year |
47,386,035,773 |
28,272,418,532 |
39,605,206,259 |
Products, Technologies, Services
Description
|
Main
Products & Services |
Medicines -Bones & Joint Disease -Cardiovascular(CV) -Central Nervous System(CNS) -Dematology -Gastrointestinal(GI) -Healthcare -Infection & Respiratory -Metabolic Disease(Endo) -Oncology Brand Name : Ursa, Luphere, Easyef |
Trade
Partners
|
Suppliers |
DAEWOONG BIO INC.(131112-0004827) 906-5, SANGSIN-RI, HYANGNAM-EUP,
HWASEONG-SI, GYEONGGI-DO, KOREA TEL:+82-31-353-5271~3 FAX:+82-31-353-5626 CHEMIE S.P.A EISAI DAINIPPON MERCK SANTE PRODESFARMA AG EDMOND PHARMA |
|
Competitors |
DONGA PHARMACEUTICAL
CO.,LTD(110111-0017990) 252, YONGDU-DONG, DONGDAEMUN-GU, SEOUL,
KOREA TEL:+82-2-920-8114 FAX:+82-2-924-2662 HANMI PHAM CO.,LTD(134811-0003187) 893-5, HAJEO-RI, PALTAN-MYEON, HWASEONG-SI,
GYEONGGI-DO, KOREA TEL:+82-31-356-3311 FAX:+82-31-356-5151 YUHAN CORPORATION(110111-0014409) 49-6, DAEBANG-DONG, DONGJAK-GU, SEOUL,
KOREA TEL:+82-2-828-0181 FAX:+82-2-828-0300 GREEN CROSS CORPORATION(110111-0109854) 303, BOJEONG-DONG, GIHEUNG-GU, YONGIN-SI,
GYEONGGI-DO, KOREA TEL:+82-31-260-9300 FAX:+82-31-260-9413 CHOONGWAE PHARMA CORP(110111-0019342) CHOONGWAE BLDG., 698, SINDAEBANG 1-DONG,
DONGJAK-GU, SEOUL, KOREA TEL:+82-2-840-6777 FAX:+82-2-841-1213 (*)The Subject is ranked as 3rd
player next to HANMI PHAM CO.,LTD(134811-0003187) in domestic market shares. |
Related Parties (Subsidiaries,
Joint-Venture & Affiliates)
|
Affiliates |
DAEWOONG CO., LTD(131111-0000271) DAEWOONG BIO INC.(131112-0004827) DAEWOONG INTERNATIONAL
CORP.(110111-0742985) R&P KOREA CO., LTD.(110111-0358021) DAEWOONG NUTRITIONS CO.,
LTD.(210111-0013294) DAEWOONG MANAGEMENT DEVELOPMENT INSTITUTE
CO., LTD.(110111-0776463 ) EZMEDICOM CO., LTD(110111-2063818) SANWONG DEVELOPMENT CO.,
LTD.(110111-0978671 ) SANWOONG ENGINEERING CO., LTD.
(134811-0034421 ) PHARMPAC CO., LTD.(134811-0048307) PAGE1 CO., LTD(110111-1771040) DAEWOONG DEVELOPMENT CO.,
LTD.(131111-0083649) IDS & TRUST CO., LTD.(110111-1234006) CG BIO CO., LTD.(174811-0035421) HR GROUP CO., LTD.(110111-2041872) BEST SYSTEM CO., LTD.(110111-1639850) JEJU MOVIELAND CO., LTD.(224111-0014832) TRUST CO., LTD. |
|
Overseas Office |
DAEWOONG PHARMACEUTICAL CO.,LTD. BEIJING RM.806, B BUILDING, YINGJIA CENTER, JIA
NO.10, EAST 3RD CIRCLE MIDDLE ROAD, CHAOYANG DISTRIC, BEIJING, CHINA TEL:+84-88-11-6441 FAX:+84-88-11-2849 DAEWOONG PHARMACEUTICAL CO., LTD. VIETNAM 69 XUAN HONG, PHUONG 12, QUAN TAN BINH THANH
PHO HO CHI MINH, VIETNAM TEL:+84-8-910-2114-16 FAX:+84-8-910-2117 PT. DAEWOONG PHARMACEUTICAL COMPANY
INDONESIA WISMA BARITO PACIFIC 4FL. JL. 5 PARMAN KAV
62-63 JAKARTA, INDONESIA TEL:+62-81-318-763-801 / 070-7895-4866 DAEWOONG PHARMACEUTICAL CO.,LTD. THAILAND 209 CMIC TOWER 8TH FLOOR, SUKHUMVIT 21RD.,
ASOK KLONG TOEY NUA, WATTANA, BANGKOK 10110 TEL:+66-2-664-2269 FAX:+66-2-664-2268 /
070-7897-0426 |
|
Liaison Office |
INDIA LIAISON OFFICE UNIT NO.1, FIRST FLOOR, KHANCHAND
TOWERS-3-190/1 PREMNAGAR, ROAD NO.1 BANJARA HILLS, HYDERABAD 500034, INDIA TEL:+91-40-66776633~4 FAX:+91-40-66776632 |
|
Subsidiary |
BIO ALPA CO., LTD.(110111-1904518 ) (70.00%held by the subject company) D&P NATUTRAL RESOURCES RESEARCH
INSTITUTE(134511-0102026) (60.00% held by the subject company) HEALIENCE CO., LTD(110111-3265778) (50.00%held by the subject company) BIO AGE CO., LTD. (71.53% held by the subject company) MDWEL INC(110111-3716854) (50.00% held by the subject company) DAEWOONG PHARM PHILIPPINES,INCORPORATED (100.00% held by the subject company) BEIJING DAEWOONG PHARMACEUTICAL R&D
CENTER CO., LTD. (100.00% held by the subject company) DAEWOONG PHARMACEUTICAL(THAILAND)CO., LTD (100.00% held by the subject company) |
|
Cooperative Enterprise |
-Domestic Sales Right DAINIPPON PHARMACEUTICAL CO., LTD. ALLERGAN ASIA LTD. EISAI CO., LTD. SANKYO CO., LTD. ENGELHARD AZNEIMITTEL SATO PHARMACEUTICAL CO., LTD. NYCOMED GSK KOREA ITALFARMACO SP.P.A. DUSA PHARMACEUTICALS, INC., EISAI CO., LTD. EISAI KOREA CO., LTD. SATO PHARMACEUTICAL CO., LTD. EURAND BRUSCHETTINI PFM BIO MED SCIENCE -Insured Company DONGBU INSURANCE CO., LTD(110111-0095285) SAMSUNG LIFE INSURANCE CO.,
LTD.(110111-0005953) KYOBO LIFE INSURANCE CO.,
LTD(110111-0014970) KOREA LIFE INSURANCE CO.,LTD(110111-0003204) |
Sales by
Region (Activity &
Markets)
|
Sales/ Unit
:Mil KRW |
2007 |
2006 |
2005 |
|
Export |
4,800 |
1,513 |
1,050 |
|
Domestic |
479,442 |
398,930 |
337,116 |
|
Total |
484,242 |
400,443 |
338,166 |
The Subject exports to Vietnam, Indonesia,
Thailand and India.
Court
Action
|
Case No. |
Court |
Plaintiff(s)/
Creditor(s)/ Applicant(s) |
Defendant(s)/
Debtor(s)/ Respondent(s) |
Cause |
Amount (KRW) |
Status |
|
|
Seoul High Court |
The Subject Company |
HANMI COMMERCIAL CO., LTD.(110111-0503593) |
Claim for Damages |
1,009,303,000 |
The Subject was defeated at 1st Round. 2nd Round
Proceeding |
|
|
Seoul Central District Court |
The Subject Company |
Lilly Korea Limited(110111-0339328) |
Commission |
4,086,900,000 |
1st Round Proceeding |
|
|
Seoul Central District Court |
Shinwoo Medical Co., Ltd. |
The Subject Company |
Claim for Damages |
1,400,000,000 |
1st Round Proceeding |
|
|
Gangnam Police Office |
Shinwoo Medical Co., Ltd. |
The Subject Company & BIO ALPA CO.,
LTD.(110111-1904518 ) & PH.D. Lee Hyun-Seung |
Violation on The Law of Medical Equipment |
260,000,000 |
1st Round Proceeding |
|
|
Seoul Central District Court |
Sanopia Pentis Co., Ltd. |
The Subject Company |
Infringement of Patents |
50,000,000 |
1st Round Proceeding |
News
Clipping
KOREAN CANCER DRUG MARKET GROWS
JOONGANGILBO & JOINS.COM:02/15/2008
The nation’s anti-cancer medicine industry is growing rapidly as the number
of cancer patients steadily increases along with life expectancy.
Multinational drug companies have started to try their hand at
developing new anti-cancer medicines, and Korea’s firms are following suit.
The technology used to produce anti-cancer medicines is also improving,
and it has become easier for more drug companies to produce unique medicines
like Gleevec, industry experts said.
Gleevec, which is used to fight chronic leukemia, targets specific cancer
cells.
According to U.S.-based IMS Health, a healthcare-industry marketing
firm, the world’s anti-cancer medicine market has increased 22 percent annually
for the past five years.
Sales of anti-cancer medicine in the Korean market reached 250 billion
won last year, marking 15 percent annual growth for the past three years.
In order to capitalize on the boom, multinational drug companies such as
Bayer, Pfizer and GlaxoSmithKline have launched new lines of anti-cancer drugs.
Bayer HeathCare, a subsidiary of Bayer, released its first such product,
Nexavar, in the Korean market last April.
“We’re waiting to get another approval on our liver cancer medicine so
that we can commercialize it,” said Lee Jae-won, a director at the firm.
“Many multinational drug manufacturers are trying to find new
anti-cancer medicines,” Lee added.
The nation’s drug companies are also trying to keep pace with
multinational competitors.
Daewoong Pharmaceutical strengthened its anti-cancer department recently
and set its sights on achieving 100 billion won in sales by 2010 with its
anti-cancer medicines.
The company plans to produce 11 types of cancer treatments that will
treat pancreatic, lung and breast cancers, among others.
Hanmi Pharmaceutical and Daewha Pharm are in the midst of transforming
the injected anti-cancer drug Taxol into tablets.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.49.46 |
|
UK Pound |
1 |
Rs.73.17 |
|
Euro |
1 |
Rs.62.96 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)